J Am Pharm Assoc (2003). 2021 Jul-Aug;61(4S):S49-S56. doi: 10.1016/j.japh.2021.02.012. Epub 2021 Mar 2.
The Agricultural Improvement Act of 2018 legalized the commercial use of hemp-based products, including cannabidiol (CBD). However, the U.S. Food and Drug Administration (FDA) does not currently regulate the commercial sale of hemp oil-based CBD, and there is no FDA-approved indication for its nonprescription formulations despite the growing demand for, and use of, hemp oil-based CBD.
Characterize the use of hemp oil-based CBD, including brands, formulations, and reasons for use, in a community pharmacy setting and identify the perceived barriers related to the use of hemp oil-based CBD.
A pretested 17-question survey was distributed at the point of care at 2 community pharmacy locations and at hemp oil-based CBD education presentations over a 3-month period. The survey consisted of multiple-choice, open-ended, and select-all-that-apply questions, which were analyzed using univariate and bivariate analyses.
A total of 101 participants completed the survey: 38 were CBD-naive, and 63 were CBD-exposed. Most of the participants were women (79%) and Caucasian (81.6%), with an average age of 59 years (SD 17.26). In the CBD-naive group, the most commonly stated barrier to using hemp oil-based CBD was not enough information about the product. Among the participants who had used or were using at least 1 CBD product, the most commonly used dosage form was sublingual, followed by topical: 46 (46/63 [73%]) and 34 (34/63 [54%]) participants, respectively. Thirty-eight participants used hemp oil-based CBD for pain, 24 participants for sleep, and 17 participants for anxiety. Of these, 62% of the participants informed a health care provider that they were using a hemp oil-based CBD product.
The participants were using different brands and formulations of hemp oil-based CBD for multiple reasons. The greatest barrier to trying CBD was limited education, which may suggest a need for community education about hemp oil-based CBD products.
2018 年《农业改进法案》使以大麻为基础的产品（包括大麻二酚，CBD）的商业使用合法化。然而，美国食品和药物管理局（FDA）目前并不监管大麻油基 CBD 的商业销售，尽管对大麻油基 CBD 的需求和使用不断增长，但也没有 FDA 批准的非处方配方。
在社区药房环境中描述大麻油基 CBD 的使用情况，包括品牌、配方和使用原因，并确定与使用大麻油基 CBD 相关的感知障碍。
在 2 家社区药房的护理点和大麻油基 CBD 教育讲座期间，分发了一份经过预测试的 17 个问题的调查。调查包括多项选择题、开放式问题和选择所有适用的问题，使用单变量和双变量分析进行分析。
共有 101 名参与者完成了调查：38 名是 CBD 新手，63 名是 CBD 暴露者。大多数参与者是女性（79%）和白种人（81.6%），平均年龄为 59 岁（SD 17.26）。在 CBD 新手组中，使用大麻油基 CBD 的最常见障碍是对产品的信息了解不足。在至少使用过 1 种 CBD 产品的参与者中，最常用的剂型是舌下，其次是局部：46 名（46/63 [73%]）和 34 名（34/63 [54%]）参与者，分别。38 名参与者使用大麻油基 CBD 治疗疼痛，24 名参与者使用大麻油基 CBD 治疗睡眠，17 名参与者使用大麻油基 CBD 治疗焦虑。其中，62%的参与者告知医疗保健提供者他们正在使用大麻油基 CBD 产品。
参与者出于多种原因使用不同品牌和配方的大麻油基 CBD。尝试 CBD 的最大障碍是有限的教育，这可能表明需要对大麻油基 CBD 产品进行社区教育。
